View Discovery

Clinical Pipeline

Learn more about our pipeline

Trials for Market Approval Download PPT

Pre-Clinical (GLP)

Institute of Materia Medica, CAMS & PUMC
National Centre of Oceanic and Antarctic Research (NCAOR), Gao, India
Guangzhou Institute of Respiratory Medicine Company Limited, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China
Microbiotix, Inc.

Phase 1

Bill & Melinda Gates Medical Research Institute, Merck & Co., Inc., NIAID, NIH, DHHS
GlaxoSmithKline, TB Drug Accelerator, Bill & Melinda Gates Foundation
TB Alliance, ERA4TB (European Regimen Accelerator for Tuberculosis), University of Auckland, Merck & Co., Inc.
TB Alliance, Institute of Materia Medica
iM4TB - Innovative Medicines for Tuberculosis, Bill & Melinda Gates Foundation
Institute of Materia Medica, CAMS & PUMC

Phase 2

GlaxoSmithKline, Bill & Melinda Gates Foundation
Shanghai Jiatan Biotech Ltd., subsidiary of Guangzhou JOYO Pharma Ltd., Shanghai, China
University of Munich, Hans-Knöll Institute, Jena, German Center for Infection Research (DZIF), European and Developing Countries Clinical Trials Partnership (EDCTP), Radboud University
BioVersys AG, GlaxoSmithKline
Spero Therapeutics, LLC, Bill & Melinda Gates Medical Research Institute
Qurient Co., Ltd, Qurient Co. Ltd. / LLC "Infectex", a portfolio firm of Maxwell Biotech Venture Fund
TB Alliance, Bill & Melinda Gates Medical Research Institute, Foundation for Neglected Disease Research
Sequella, Inc
NIAID, NIH, DHHS, Bill & Melinda Gates Foundation, EDCTP
CDC TBTC, NIAID, NIH, DHHS, Boston University